INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER Journal
Overview
publication venue for
- Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial 2024
- Neoadjuvant chemotherapy with bevacizumab for locally advanced vulvar cancer. 34:977-984. 2024
- Efficacy and safety of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy 2023
- Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial 2023
- A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. 33:1458-1463. 2023
- A PHASE I/II STUDY EVALUATING INTRAPERITONEAL GEN-1 IN COMBINATION WITH NEOADJUVANT CHEMOTHERAPY IN PATIENTS NEWLY DIAGNOSED WITH ADVANCED EPITHELIAL OVARIAN CANCER 2022
- CERVICAL CANCER TREATED BY NEOADJUVANT CHEMOTHERAPY FOLLOWED BY RADICAL SURGERY: A CASE SERIES FROM MIREBALAIS, HAITI 2022
- MALIGNANT PERITONEAL CYTOLOGIC CONTAMINATION WITH ROBOTIC HYSTERECTOMY FOR ENDOMETRIAL CANCER 2022
- OVERALL SURVIVAL RESULTS FROM ARIEL3: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA 2022
- PHASE 3 STUDY OF EFFICACY & SAFETY OF OLVI-VEC AND PLATINUM-DOUBLET plus BEVACIZUMAB COMPARED TO PLATINUM-DOUBLET plus BEVACIZUMAB IN PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER (ONPRIME; GOG-3076) [NCT05281471] 2022
- Executive summary of the American Radium Society appropriate use criteria for management of uterine clear cell and serous carcinomas. 32:1549-1554. 2022
- CLINICAL AND MOLECULAR CHARACTERISTICS OF ARIEL3 PATIENTS WHO DERIVED EXCEPTIONAL BENEFIT FROM RUCAPARIB MAINTENANCE TREATMENT FOR HIGH-GRADE OVARIAN CANCER (HGOC) 2021
- Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. 31:949-958. 2021
- EFFICACY OF CHECKPOINT INHIBITOR IMMUNOTHERAPY DRUG PEMBROLIZUMAB (KEYTRUDA) FOR TREATMENT OF ADVANCED CERVICAL CANCER 2021
- SAFETY PROFILE OF KEYTRUDA (PEMBROLIZUMAB) FOR THE TREATMENT OF PATIENTS WITH ADVANCED PD-L1 POSITIVE CERVICAL CANCER 2021
- FREQUENCY AND MOLECULAR ASSOCIATIONS OF KRAS MUTATIONS IN GYNECOLOGIC MALIGNANCIES 2020
- KRAS MUTANT UTERINE CARCINOMAS 2020
- ONCOLYTIC VACCINIA (OLVI-VEC) PRIMED IMMUNOCHEMOTHERAPY IN PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER 2020
- POSTPROGRESSION EFFICACY OUTCOMES FROM THE PHASE 3 ARIEL3 STUDY OF RUCAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CARCINOMA ASSOCIATED WITH EITHER BRCA1 OR BRCA2 MUTATIONS 2020
- Robotic-assisted laparoscopic splenectomy for recurrent ovarian cancer. 30:1189-1194. 2020
- Robotic sentinel lymph node (SLN) mapping in endometrial cancer: SLN symmetry and implications of mapping failure. 30:305-310. 2020
- Empowering and training front-line providers treating cervical cancer in Haiti: perspective of a gynecologic oncologist's experience with international surgical missions 2020
- EFFECT OF PROGRESSION-FREE INTERVAL (PFI) FOLLOWING PENULTIMATE PLATINUM-BASED REGIMEN ON THE EFFICACY OF RUCAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH PLATINUM-SENSITIVE, RECURRENT OVARIAN CARCINOMA: AN ANALYSIS FROM THE PHASE 3 STUDY ARIEL3 2019
- PATIENT-CENTRED OUTCOMES IN THE PHASE 3 STUDY ARIEL3 OF RUCAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH PLATINUM-SENSITIVE, RECURRENT OVARIAN CARCINOMA: POST HOC EXPLORATORY ANALYSES BY BRCA MUTATION STATUS AND PATIENT AGE 2019
- A PHASE IB STUDY OF INDIRECT IMMUNIZATION WITH OREGOVOMAB AND TLR3 STIMULATION WITH HILTONOL (R) (H) IN PATIENTS WITH RECURRENT PLATINUM RESISTANT OVARIAN CANCER (PROC) 2019
- ABO, RH, KELL AND MN SYSTEMS WITHIN UTERINE CANCER 2019
- EXPLORATORY ANALYSIS OF POSTPROGRESSION AND PATIENT-CENTERED OUTCOMES IN ARIEL3: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF RUCAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH RECURRENT OVARIAN CARCINOMA 2019
- FACTORS ASSOCIATED WITH EXTENDED SURVIVAL FOR PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (PROC) TREATED WITH MODIFIED VACCINIA ONCOLYTIC VIROTHERAPY (VOV) 2019
- SELECTED TUMOR MARKERS AND SEX-STEROID HORMONES IN BREAST TUMORS 2019
- THE ALTERATION OF LIPIDS AND STEROID HORMONES IN BREAST TUMORS 2019
- THE STUDY OF THE ANTIOXIDANT ENZYMES, THE ACTIVITY OF ACID PHOSPHATASE AND ALTERATION OF LIPID PEROXIDATION IN WOMEN WITH UTERINE TUMORS 2019
- Use of the Poly (ADP-Ribose) Polymerase Inhibitor Rucaparib in Women with Recurrent Ovarian Carcinoma with Endometrioid and Other Nonserous Histopathologic Subtypes 2018
- EFFECT OF PRIOR BEVACIZUMAB THERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CARCINOMA (ROC) IN THE PHASE 3 STUDY ARIEL3 2018
- ARIEL3: PHASE 3, RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA (OC) 2017
- ARIEL3: PHASE 3, RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA (OC) 2017
- Prognostic Significance of the Standardized Uptake Value of Pretherapeutic F-18-Labeled 2-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography in Patients With Locally Advanced Cervical Cancer. 27:530-536. 2017
- Perioperative Outcomes for Laparotomy Compared to Robotic Surgical Staging of Endometrial Cancer in the Elderly A Retrospective Cohort. 26:1717-1721. 2016
- Robotically Assisted Para-aortic Lymphadenectomy: Surgical Results A Cohort Study of 487 Patients. 25:504-511. 2015
- Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer A Phase II Study. 24:1583-1589. 2014
- ROBOTICALLY-ASSISTED PARA-AORTIC LYMPHADENECTOMY: SURGICAL RESULTS - A COHORT STUDY OF 487 PATIENTS 2013
- A Detailed Study of Patients and Tumor Characteristics of Epithelial Ovarian Cancer in Saudi Women. 23:456-460. 2013
- Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer. 22:979-986. 2012
- Should Uterine Tandem Applicators Ever Be Placed Without Ultrasound Guidance? No A Brief Report and Review of the Literature 2011
- Functional Characterization of a Fluorescent Highly Tumorigenic Ovarian Cancer Line to Test Cellular Therapy in Experimental Models. 21:457-465. 2011
- Impact of a Weekly Multidisciplinary Tumor Board Conference on the Management of Women With Gynecologic Malignancies. 20:1321-1325. 2010
- Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer. 20:772-780. 2010
- Effect of TRA-8 Anti-Death Receptor 5 Antibody in Combination With Chemotherapy in an Ex Vivo Human Ovarian Cancer Model. 19:814-819. 2009
- Patterns of Failure for Conservatively Managed Surgical Stage I Uterine Carcinosarcoma Implications for Adjuvant Therapy. 19:888-891. 2009
- Outcomes of gynecologic oncology patients admitted to the intensive care unit following surgery: a university teaching hospital experience. 16:1766-1769. 2006
- The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: Long-term results. 12:323-331. 2002
Research
category
- OBSTETRICS & GYNECOLOGY Web of Science Category
- ONCOLOGY Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 1048-891X
Electronic International Standard Serial Number (EISSN)
- 1525-1438
Other
journal abbreviation
- INT J GYNECOL CANCER